MedTrace Logo

Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients

NCT01374165 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-05-24

No results posted yet for this study

Summary

Prolong proposes to test safety, tolerability and pharmacokinetics of SANGUINATE™ in sickle cell disease (SCD) patients. Prolong's preclinical studies showed that SANGUINATE™ was safe in a number of different animal models and toxicology studies. In this Phase I trial, Prolong will test whether it is also safe and tolerable in sickle cell patients. The study will be conducted in 15 adult (\>18 years) patients.

Conditions

Sponsors & Collaborators

  • Prolong Pharmaceuticals

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01374165 on ClinicalTrials.gov